Prenetics (PRE) Q1 2026 earnings review
IM8 Hyper-Growth Continues as Crypto Distractions Are Eliminated
Prenetics delivered a transformative quarter, with IM8 revenue accelerating 23% sequentially to $33.8M (up nearly 6x YoY). The company successfully transitioned customers to quarterly subscriptions, causing a massive spike in New Customer Average Order Value (AOV) to $240, up 53% QoQ. Crucially, management quietly abandoned its 'Bitcoin Treasury Strategy' post-quarter, liquidating all digital assets for $41.3M to build a $147M war chest. With non-core segments (Europa, ACT Genomics) fully divested and crypto eliminated, Prenetics is now a pure-play consumer health company. FY26 IM8 guidance was raised to $190M-$210M, signaling confidence in sustained momentum.
🐂 Bull Case
IM8 is tracking toward $186M in Annualized Recurring Revenue (ARR) based on May 2026 estimates. The brand is successfully expanding globally, with over 60% of Q1 revenue coming from outside the US (across 43 countries).
By liquidating its Bitcoin holdings, the company eliminated balance sheet volatility and secured ~$147M in total liquidity (cash, short-term investments, and escrows) with zero debt, providing ample runway to fund marketing and expansion.
🐻 Bear Case
Despite explosive revenue growth, the company is still burning cash. Q1 Loss from Operations worsened to $8.9M from $6.0M a year ago, reflecting heavy customer acquisition and global scaling costs.
The legacy CircleDNA segment is decelerating rapidly, with revenue dropping to $2.2M (down 12% YoY). It is becoming immaterial to the broader growth narrative.
⚖️ Verdict: 🟢
Bullish. The underlying unit economics of IM8 are exceptional. The successful shift to quarterly subscriptions drove AOV to $240 and pushed gross margins to 64.3%. Exiting the volatile crypto treasury strategy is a major positive step toward institutional investability.
Key Themes
Quarterly Subscription Shift Drives AOV and Volume
A strategic push into quarterly subscription plans triggered a structural shift in unit economics. While total customer orders dipped slightly by 4% QoQ (to 220,000), total servings delivered surged 28% to over 8.8 million. Consolidating three months of demand into single orders rocketed New Customer AOV from $157 in 25Q4 to $240 in 26Q1. This improves cash conversion, reduces shipping friction, and locks in customer retention.
Strategic Reversal: Abandoning the Bitcoin Treasury
Reversing course from 2025—when management touted programmatic daily Bitcoin accumulation as a core strategy—Prenetics quietly divested its entire digital asset portfolio in April/May 2026 for $41.3M. This eliminates the massive IFRS net income volatility seen this quarter (where fair value mark-to-market losses drove up to a $26M net loss) and solidifies Prenetics as a pure-play consumer health asset.
IM8 Gross Margin Expansion
Gross margins are accelerating. IM8 delivered 64.3% in Q1 26, up ~400 basis points from Q4 25. Management attributes this to scale-driven manufacturing efficiencies, renegotiated supplier economics, packaging optimization, and the shift toward higher-margin quarterly subscription bundles (like the Beckham Stack).
Operating Leverage is Lagging Revenue Growth
While IM8 revenue grew over 300% YoY, Loss from Operations actually worsened by 48.5% YoY to $8.9M. Adjusted EBITDA also dipped further into the red at $(5.6)M compared to $(4.5)M a year ago. The company is aggressively buying market share globally; investors need to monitor when top-line scale will finally outpace marketing and fulfillment overhead to drive bottom-line profitability.
CircleDNA is Fading into Irrelevance
The legacy genetics business, CircleDNA, generated just $2.2M in Q1 (down from $2.5M YoY). It now accounts for only 6.1% of total revenue. As resources pivot entirely to IM8, CircleDNA risks becoming a stranded asset dragging on management attention.
Product Line Extension Scheduled for Q4
Innovation pipeline announced: IM8 will launch three new SKUs in Q4 2026—Hydration, Creatine, and Kids' Gummies. These represent entry into high-growth, massive TAM adjacent categories. By leveraging the existing subscriber base and the David Beckham/athlete partner halo effect, these additions should naturally boost Customer Lifetime Value (LTV) through multi-product adoption.
Other KPIs
As of mid-May 2026, total estimated liquidity consists of $91.3M in cash, ~$50M in investment funds, and $6.1M in escrow. This immense war chest was bolstered by the $41.3M digital asset sale. The company holds zero debt, giving it complete financial flexibility.
Since launching the $40M program in March 2026, the company aggressively repurchased 968,349 shares. This signals strong management conviction in the intrinsic value of the newly streamlined IM8 operation and returns real capital to shareholders.
Guidance
Accelerating. The midpoint of $47.0M implies approximately 30% sequential quarter-over-quarter growth compared to Q1's $36.0M. This proves that global momentum and the shift to quarterly subscriptions are driving sustained velocity.
Accelerating. Implies approximately 33% sequential growth over Q1's $33.8M. Management noted that April generated ~$14.0M and May is tracking to ~$15.5M, fully supporting this guidance range.
Accelerating. Raised from previous guidance of $180M-$200M. The new midpoint of $200M implies a massive leap from the ~$60.1M generated in FY25, cementing IM8 as a breakout global health brand.
Key Questions
Path to Adjusted EBITDA Profitability
With operating losses widening YoY despite explosive gross profit growth, what is the specific revenue scale required for IM8 to achieve sustainable Adjusted EBITDA profitability?
CircleDNA Strategic Alternatives
Given CircleDNA's revenue decline to just $2.2M and the total strategic pivot toward IM8, is the company actively exploring a divestiture of the genetics business?
Margin Profile of New Q4 SKUs
As IM8 expands into Hydration, Creatine, and Kids' Gummies in Q4, how will the gross margin profile of these highly competitive categories compare to the 64% margin of the flagship Daily Ultimate Essentials Pro?
Marketing Spend Ratio
In previous quarters, guidance targeted marketing spend at 45-50% of revenue. With AOV jumping to $240, has the Day-1 CAC recovery profile improved enough to lower this ratio in the second half of 2026?